Literature DB >> 2924372

Effect of homoharringtonine on the viability of murine leukemia P388 cells resistant to either adriamycin, vincristine, or 1-beta-D-arabinofuranosylcytosine.

L J Wilkoff1, D A Dulmadge, W R Laster, D P Griswold.   

Abstract

Cultured murine leukemia P388 cell populations were derived from P388 cells resistant to vincristine (P388/VCR), adriamycin (P388/ADR), and 1-beta-D-arabinofuranosylcytosine (P388/ARA-C) that were developed in vivo and to the parental drug-sensitive cells (P388/O) that were passaged in vivo. The doubling times of the cultured cell populations (mean +/- SD) between cell densities of 5 x 10(4) and 1 x 10(6) cells/ml were 14.2 +/- 2 h (P388/O), 16.5 +/- 1.9 h (P388/VCR), 16.9 +/- 1.2 h (P388/ADR), and 15.0 +/- 1.4 h (P388/ARA-C). Exponentially proliferating cultured cell populations were exposed to selected homoharringtonine (HHT) concentrations for 24 h and the surviving cell fractions were determined by colony formation in semisolid medium. The results, based on differential sensitivity of the cell populations to HHT, indicated that cultured P388/VCR cells were cross-resistant to 0.018-1.8 micrograms/ml HHT, P388/ADR cells were cross-resistant to 0.058-1.8 micrograms/ml HHT, and P388/ARA-C cells were collaterally sensitive to 0.09-0.36 micrograms/ml HHT. The results with the cultured P388/VCR, P388/ADR, P388/ARA-C, and P388/O cell populations were confirmed in animal experiments. CD2F1 mice bearing intraperitoneal (i.p.) implants of 1 x 10(6) P388/VCR, P388/ADR, P388/ARA-C, or P388/O leukemia cells were given HHT i.p. qd on days 1-9 postimplantation. Optimal treatment (less than or equal to LD10) produced in vivo cell kills of 2 to 3 log10 units in P388/O and about 7 log10 units in P388/ARA-C, whereas P388/VCR and P388/ADR cells actually increased by 1-2 log10 units during treatment. The results of this study indicate that cross-resistance (P388/VCR and P388/ADR) or collateral sensitivity to HHT (P388/ARA-C) is a function of the cellular properties of the target tumor cell populations that is independent of host factors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2924372     DOI: 10.1007/BF00267945

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  28 in total

1.  Harringtonine, an inhibitor of initiation of protein biosynthesis.

Authors:  M T Huang
Journal:  Mol Pharmacol       Date:  1975-09       Impact factor: 4.436

2.  Isolation and characterization of DNA sequences amplified in multidrug-resistant hamster cells.

Authors:  P Gros; J Croop; I Roninson; A Varshavsky; D E Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

Review 3.  Cancer chemotherapy.

Authors:  A C Sartorelli; W A Creasey
Journal:  Annu Rev Pharmacol       Date:  1969       Impact factor: 13.820

4.  A survey of commercially available tissue culture media.

Authors:  H J Morton
Journal:  In Vitro       Date:  1970 Sep-Oct

5.  Experimental evaluation of potential anticancer agents. XIX. Sensitivity of nondividing leukemic cell populations to certain classes of drugs in vivo.

Authors:  F M Schabel; H E Skipper; M W Trader; W S Wilcox
Journal:  Cancer Chemother Rep       Date:  1965-10

6.  Leukemic cell differentiation in vivo and in vitro: arrest of proliferation parallels the differentiation induced by the antileukemic drug Harringtonine.

Authors:  A W Boyd; J R Sullivan
Journal:  Blood       Date:  1984-02       Impact factor: 22.113

7.  Phase I trial of homoharringtonine administered by prolonged continuous infusion.

Authors:  J A Neidhart; D C Young; E Kraut; B Howinstein; E N Metz
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

8.  Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines.

Authors:  N Kartner; J R Riordan; V Ling
Journal:  Science       Date:  1983-09-23       Impact factor: 47.728

9.  Uptake, initial effects, and chemotherapeutic efficacy of harringtonine in murine leukemic cells sensitive and resistant to vincristine and other chemotherapeutic agents.

Authors:  T C Chou; F A Schmid; A Feinberg; F S Philips; J Han
Journal:  Cancer Res       Date:  1983-07       Impact factor: 12.701

10.  Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells.

Authors:  I B Roninson; J E Chin; K G Choi; P Gros; D E Housman; A Fojo; D W Shen; M M Gottesman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

View more
  3 in total

1.  Comparative efficacy and safety of eleven induction chemotherapy regimens for young adult patients with newly diagnosed acute myeloid leukemia: a network meta-analysis.

Authors:  Yiqing Li; Ting Tang; Jie Xiao; Boqi Li; Wenjuan Yang; Shuangfeng Xie; Yumo Du; Kezhi Huang; Danian Nie
Journal:  Ann Hematol       Date:  2022-04-20       Impact factor: 3.673

2.  Etoposide-resistant human colon and lung adenocarcinoma cell lines exhibit sensitivity to homoharringtonine.

Authors:  L J Wilkoff; E A Dulmadge; G Vasanthakumar; J P Donahue
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.

Authors:  V Lévy; S Zohar; C Bardin; A Vekhoff; D Chaoui; B Rio; O Legrand; S Sentenac; P Rousselot; E Raffoux; F Chast; S Chevret; J P Marie
Journal:  Br J Cancer       Date:  2006-07-18       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.